gyki 52466 has been researched along with cx 614 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, AC; Kessler, M; Lynch, G; Rogers, G | 1 |
| Scriabine, A | 1 |
2 other study(ies) available for gyki 52466 and cx 614
| Article | Year |
|---|---|
Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466.
Topics: Alanine; Animals; Anti-Anxiety Agents; Benzodiazepines; Benzothiadiazines; Cells, Cultured; Diuretics; Drug Interactions; Electrophysiology; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Hippocampus; Humans; In Vitro Techniques; Male; Oxazines; Pyrimidinones; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Recombinant Proteins; Sodium Chloride Symporter Inhibitors; Tritium; Uracil | 2000 |
The Neurobiology and Neuropharmacology of Alzheimer's Disease. The ASPET - Ray Fuller Symposium. New Orleans, LA, USA, April 19-20, 2002.
Topics: Alzheimer Disease; Animals; Anti-Anxiety Agents; Benzodiazepines; Benzothiadiazines; Humans; Neurobiology; Neuropharmacology; Neuroprotective Agents; Oxazines | 2002 |